HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients With EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials
Roles
Author
Document Type
Article
Publication Date
1-1-2025
Publication Title
Journal of the National Comprehensive Cancer Network
DOI
10.6004/jnccn.2024.7315
Recommended Citation
Jones, D. T., Hussain, A., Aboaid, H., Hattin, R., Schauer, S., Schlesinger, T., Twells, R., Aharonian, K., Parto, R., Rahmani, R., Lambert-Swainston, C., Srinvasmurthy, R., & Thein, K. Z. (2025). HSR25-171: Risk of Health-Related Quality of Life (HRQOL) Events in Patients With EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated With Amivantamab: A Meta-Analysis of Phase III Randomized Controlled Trials. Journal of the National Comprehensive Cancer Network, 23 (3.5), Article HSR25-171. https://doi.org/10.6004/jnccn.2024.7315
